MBAIHealthcare · Diagnostics & ResearchMBAI Stock Forecast: Check-Cap Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 8 of 100 as at 1 Aug 2026 — in the weakest quartile.
MBAI stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Check-Cap Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Quality (1): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Check-Cap Ltd. — and when they’d sell — is the membership.
MBAI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MBAI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MBAI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Check-Cap Ltd. (MBAI) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 1.6×
- Price / sales
- —
- Price / book
- 2.2×
- EV / EBITDA
- −3.3×
Cheaper than 70% of US stocks
Cheaper than 44% of US stocks
Cheaper than 76% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- 416.7%
- Return on assets
- −37.7%
- Dividend yield
- —
Higher than 99% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
MBAI vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MBAI appears on the weeks it earns a place.
Frequently asked questions about MBAI stock
How does Ticker Nerd's model rank MBAI?
As at 1 Aug 2026, Check-Cap Ltd. ranks 8 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
What is the MBAI stock forecast for 2030?
No analyst covering Check-Cap Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MBAI are extrapolating price history, which says nothing about the business.
How has MBAI stock performed over the past year?
Check-Cap Ltd. returned +66.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Check-Cap Ltd. do?
Check-Cap Ltd. is a clinical-stage medical diagnostics company based in Israel, specializing in the development of innovative capsule-based screening technology for colorectal cancer detection.
About Check-Cap Ltd.
Check-Cap Ltd. is a clinical-stage medical diagnostics company based in Israel, specializing in the development of innovative capsule-based screening technology for colorectal cancer detection. Founded in 2004, the company focuses on its proprietary C-Scan system, which includes an ingestible capsule that uses ultra-low-dose X-rays to non-invasively scan the inner lining of the colon for precancerous polyps and structural abnormalities. This capsule-based approach aims to provide patient-friendly, preparation-free colorectal screening to increase adherence and enable early intervention. The system comprises the C-Scan capsule, a disposable tracking device attached externally to the patient, and analytic software for data processing and report generation. Check-Cap's technology represents a significant advancement in non-invasive cancer diagnostics, aligning with the broader healthcare sector's focus on early detection and preventive medicine.
CEO Mr. David Lontini · 85 employees · Israel · https://check-cap.com